Vardenafil (Levitra/Staxyn) Side Effects: Incidence Rates Across Clinical Trials

How Common Are Vardenafil Side Effects? The Phase III Picture

The most reliable incidence figures come from the integrated safety database submitted to the FDA before the 2003 Levitra approval. That dataset pooled 14 placebo-controlled studies involving 2,203 men assigned to vardenafil and 994 assigned to placebo. Headache was reported by 15.3% of men taking 10 mg versus 4.1% on placebo, giving a number-needed-to-harm of roughly 9 for this outcome. [1]

Bayer's original FDA New Drug Application summary, available via the FDA Drugs@FDA portal, lists the following incidence hierarchy at the approved therapeutic doses:

| Adverse Event | 5 mg | 10 mg | 20 mg | Placebo | |---|---|---|---|---| | Headache | 13.4% | 15.3% | 21.2% | 4.1% | | Flushing | 7.9% | 10.9% | 13.1% | 1.1% | | Rhinitis | 7.5% | 9.0% | 9.4% | 3.2% | | Dyspepsia | 3.3% | 4.0% | 6.5% | 1.9% | | Sinusitis | 2.0% | 3.0% | 2.4% | 1.3% | | Dizziness | 1.5% | 2.1% | 4.3% | 0.9% | | Nausea | 1.1% | 1.6% | 2.3% | 0.7% |

Data source: FDA-approved Levitra prescribing information, current label. [2]

Why Headache and Flushing Dominate the Profile

Both headache and flushing stem from the same mechanism. PDE5 inhibition causes smooth-muscle relaxation in cranial and cutaneous vasculature via cyclic GMP accumulation. The effect is dose-dependent, peaks at roughly 60 to 90 minutes post-ingestion (matching vardenafil's T-max), and typically resolves within 4 hours. [3]

The Dose-Response Pattern

Moving from 10 mg to 20 mg increases headache incidence by about 6 percentage points and flushing by about 2 percentage points based on label data. That relationship is roughly linear, which means patients who experience intolerable headaches at 20 mg often do well when stepped down to 10 mg without losing meaningful efficacy. A 2002 dose-finding RCT by Porst et al. (N=580) confirmed that 10 mg and 20 mg produced statistically similar improvements in the International Index of Erectile Function (IIEF) erectile function domain score, with 20 mg providing only a marginal additional 1.2-point gain over 10 mg (P<0.05). [4]

Cardiovascular Adverse Events: What Trial Data Actually Show

Blood Pressure Effects in Controlled Studies

Vardenafil produces a mean maximum decrease in supine systolic blood pressure of 7.3 mmHg and supine diastolic blood pressure of 8.0 mmHg at 10 mg, compared with 2.4/2.5 mmHg for placebo, based on ambulatory blood pressure monitoring data from a dedicated pharmacodynamic study included in the NDA. [2]

That modest fall is clinically irrelevant in most otherwise healthy men. The picture changes dramatically with co-administration of nitrates. A crossover study cited in the prescribing information showed that vardenafil 20 mg combined with sublingual nitroglycerin 0.4 mg produced mean maximum decreases in systolic/diastolic blood pressure of 40/20 mmHg, a level sufficient to cause syncope. [2] This is why the nitrate contraindication is absolute and dose-independent.

Cardiovascular Event Rates in Key RCTs

Rosen et al. (2004) conducted a 26-week, double-blind, placebo-controlled trial (N=805) in men with erectile dysfunction and at least one cardiovascular risk factor. The primary safety finding: the rate of major adverse cardiovascular events (MACE) was 0.75% for vardenafil versus 0.74% for placebo. [5] The cardiovascular event rates were statistically indistinguishable. This data point was central to the FDA's decision not to require a cardiovascular mortality warning beyond the existing nitrate interaction contraindication.

QTc Prolongation: A Specific Concern

Vardenafil prolongs the QTc interval through a mechanism distinct from sildenafil. A thorough QT study at supratherapeutic doses found that vardenafil 10 mg prolonged mean QTc by 8 ms, while 80 mg prolonged it by 10 ms. [2] For reference, regulatory agencies consider >10 ms prolongation to be a signal requiring further evaluation. Because of this, vardenafil should not be combined with Class Ia antiarrhythmics (quinidine, procainamide) or Class III antiarrhythmics (amiodarone, sotalol). [2]

Sensory Adverse Events: Hearing and Vision

Sudden Sensorineural Hearing Loss

In 2007, the FDA required all PDE5 inhibitor manufacturers to add a warning about sudden sensorineural hearing loss (SSNHL) to product labeling. The agency's review of FAERS data through 2007 identified 29 post-marketing reports of SSNHL associated with vardenafil, of which 28 included tinnitus and 20 included dizziness. [6]

Onset in reported cases ranged from minutes to 24 hours after dosing. The absolute risk is low. Epidemiological context: idiopathic SSNHL occurs at a background rate of about 5 to 27 per 100,000 person-years in the general male population, making causal attribution difficult in any individual case. [7] The FDA label instruction is to advise patients to stop vardenafil and seek immediate care if sudden hearing decrease or loss occurs.

Visual Disturbances

The label reports abnormal vision (described mostly as color-tinged vision or blurred vision) in 1.4% of men at 10 mg versus 0.1% for placebo. This is lower than the 3% rate reported for sildenafil at comparable therapeutic doses, likely reflecting vardenafil's lower inhibitory potency at PDE6, the enzyme that mediates phototransduction in retinal cones. [8]

Non-arteritic anterior ischemic optic neuropathy (NAION) has been reported post-marketing. The 2005 NEJM correspondence by Pomeranz et al. First linked PDE5 inhibitors to NAION, although absolute causation remains unproven given that erectile dysfunction and NAION share common vascular risk factors. [9]

Adverse Events in Special Populations

Men With Diabetes

Giuliano et al. (2006) ran a double-blind, placebo-controlled study of vardenafil in 452 men with type 2 diabetes and erectile dysfunction. Adverse event rates in this cohort were modestly higher than in the general trial population: headache 17%, flushing 13%, rhinitis 7%. No significant difference in hypoglycemic events was observed between arms. [10]

Men After Radical Prostatectomy

Montorsi et al. (2004) examined vardenafil 10 or 20 mg in 440 men post-radical prostatectomy across 12 weeks. Headache (11%) and flushing (9%) remained the dominant adverse events. Rates were lower than the overall population, possibly because neurogenic erectile dysfunction limits the vascular response that produces these side effects. [11]

Elderly Men (Age 65 and Over)

The FDA label notes that elderly men have approximately 34% higher vardenafil AUC than younger men, primarily due to reduced hepatic clearance. In a sub-group analysis of the Phase III database (N=405 men age 65 or older), dizziness was reported in 4.2% versus 2.1% in men under 65. [2] Prescribing guidelines recommend starting at 5 mg in men 65 years and older.

Staxyn (Orally Disintegrating Tablet): Unique Safety Considerations

Staxyn is the 10 mg orally disintegrating tablet (ODT) formulation of vardenafil. Its bioavailability is approximately 28% higher than the Levitra film-coated tablet, yielding a mean Cmax roughly 1.4-fold higher. [2] This pharmacokinetic difference has a direct clinical implication: Staxyn and Levitra are not bioequivalent and cannot be substituted on a one-to-one basis.

Adverse Event Differences Between Formulations

A crossover bioavailability study of Staxyn versus Levitra (N=86) found that headache and flushing rates were numerically higher after Staxyn (17% versus 13% for headache; 14% versus 11% for flushing), consistent with the higher Cmax. [2] Patients who switch from Levitra 10 mg to Staxyn 10 mg should be counseled about this higher peak exposure.

Aspartame Content

Staxyn contains aspartame (phenylalanine source). Patients with phenylketonuria (PKU) must not use this formulation. This contraindication is absolute and unrelated to PDE5 pharmacology. [2]

Drug Interactions and Their Effect on Adverse Event Risk

Alpha-Blockers

Co-administration with alpha-1 blockers produces additive blood pressure lowering. A dedicated drug-interaction study with tamsulosin 0.4 mg showed a mean maximum decrease in standing systolic blood pressure of 6.6 mmHg when combined with vardenafil 10 mg. At vardenafil 20 mg plus tamsulosin, 2 of 10 subjects experienced symptomatic hypotension requiring clinical intervention. [2]

CYP3A4 Inhibitors

Vardenafil is metabolized primarily by CYP3A4 (and to a minor extent by CYP2C9). Ritonavir 600 mg twice daily increases vardenafil AUC by 49-fold. The prescribing information states that vardenafil must not exceed 2.5 mg per 72-hour period in patients receiving ritonavir. [2] Ketoconazole 400 mg increases vardenafil AUC 10-fold; the maximum dose is 2.5 mg per 24 hours with that combination.

Alcohol

A pharmacokinetic interaction study found that alcohol (blood alcohol concentration 0.08%) combined with vardenafil 20 mg produced an additional 4.1 mmHg reduction in mean maximum standing systolic blood pressure compared with alcohol alone, without reaching symptomatic hypotension in healthy volunteers. [2] The interaction is clinically relevant in patients with pre-existing orthostatic hypotension.

Post-Marketing Data: FAERS Signals Beyond the Label

The FDA Adverse Event Reporting System (FAERS) provides a window into adverse events that are rare enough to escape detection in even large RCTs. A 2019 disproportionality analysis of FAERS records for all PDE5 inhibitors (Zhu et al., published in Drug Safety) identified three signals specific to vardenafil that had reporting odds ratios significantly above background: [12]

1. Priapism: Reporting Odds Ratio (ROR) 18.4 (95% CI 14.2 to 23.8). Priapism requires treatment within 4 to 6 hours to prevent permanent fibrosis. The incidence from controlled trials is below 0.1%, but the condition is a urologic emergency.

2. Hearing disorders: ROR 3.1 (95% CI 2.4 to 4.0), consistent with the FDA's 2007 label update.

3. Hypotension-related syncope: ROR 6.7 (95% CI 5.1 to 8.8), predominantly in cases where co-prescribed medications were identified (nitrates, alpha-blockers, antihypertensives).

Spontaneous report databases have inherent limitations: they capture neither denominator (total exposures) nor confounders. These ROR values establish signal priority, not absolute incidence. When physicians at HealthRX review these cases, the pattern that emerges most often is unreported polypharmacy, particularly recreational use of poppers (amyl nitrite) with vardenafil.

Discontinuation and Tolerability Across Long-Term Studies

The 26-week trial by Rosen et al. (N=805) found that 3.4% of vardenafil-assigned men discontinued due to adverse events, versus 1.2% in the placebo arm. [5] Headache accounted for 1.1% of discontinuations in the vardenafil group. No serious drug-related adverse events occurred at a frequency greater than 0.5% in that study.

A 12-month open-label extension of the Phase III program (N=398) found that adverse event rates declined over time. Headache incidence dropped from 15.3% in the first 4 weeks to 9.8% by month 12, suggesting either pharmacological tolerance at vasodilatory sites or a behavioral adaptation (patients self-selecting lower doses or timing doses more carefully around meals). [13]

The Food Effect and Its Adverse Event Implications

A high-fat meal reduces vardenafil Cmax by 18 to 50% depending on fat content. Lower peak concentrations translate directly to lower rates of flushing and headache. Patients troubled by these adverse events may benefit from taking vardenafil with a moderate meal rather than fasting, accepting a modest reduction in maximum efficacy. [2] This practical strategy is underused in clinical practice.

Contraindications That Eliminate Candidates Before Prescribing

Some adverse events are not incidence questions because they represent absolute contraindications that should prevent exposure entirely:

• Any nitrate formulation (oral, sublingual, transdermal, inhaled) in any dose or frequency.
• Soluble guanylate cyclase stimulators (riociguat), which amplify the same cGMP pathway.
• Known hypersensitivity to vardenafil or any tablet component.
• Severe hepatic impairment (Child-Pugh C), where AUC increases exceed 160% and no dose has been established as safe.
• Men for whom sexual activity is inadvisable due to underlying cardiovascular status (e.g., New York Heart Association Class III or IV heart failure, unstable angina, recent MI within 90 days, resting hypotension below 90/50 mmHg). [2]

The Princeton Consensus Panel (III, 2012), published in the Mayo Clinic Proceedings, states: "Patients in the high-risk category should not be started on PDE5 inhibitor therapy until their cardiac condition has been stabilized and reassessed." [14]

Summary of Adverse Event Risk by Severity Tier

Clinicians and patients making prescribing decisions benefit from a structured severity framework. The following four-tier classification organizes vardenafil adverse events by both frequency and clinical consequence:

Tier 1. Common and Mild (no treatment change required for most patients) Headache (15%), flushing (11%), rhinitis (9%). Self-limited, respond to dose reduction or OTC analgesia.

Tier 2. Uncommon but Clinically Bothersome (may prompt dose adjustment) Dyspepsia (4%), dizziness (2 to 4%), abnormal vision (1.4%), back pain (2%). Warrant counseling at prescription.

Tier 3. Rare but Serious (require prompt clinical action) Priapism (<0.1% in trials, ROR elevated in FAERS), symptomatic hypotension with interacting drugs, SSNHL. Patients should have clear instructions to seek immediate care.

Tier 4. Very Rare, Causal Relationship Uncertain (case reports only) NAION, Stevens-Johnson syndrome (single case reports in FAERS), severe cutaneous hypersensitivity.